Warning: Use of undefined constant ana - assumed 'ana' (this will throw an Error in a future version of PHP) in /home/34/43/7004334/web/nanotechnology/nanomaterial/nanobiomedicine_plist.php on line 17

Warning: Use of undefined constant fabr - assumed 'fabr' (this will throw an Error in a future version of PHP) in /home/34/43/7004334/web/nanotechnology/nanomaterial/nanobiomedicine_plist.php on line 20

Warning: Use of undefined constant drug - assumed 'drug' (this will throw an Error in a future version of PHP) in /home/34/43/7004334/web/nanotechnology/nanomaterial/nanobiomedicine_plist.php on line 23
Nanobiotechnology and Nanomedicine Companies; category Delivery, page 2
 

Nanobiotechnology and Nanomedicine Companies

 

Showing results 21 - 40 of 40 for suppliers of Delivery:

 
Living Cell is developing cell-based products to treat life threatening human diseases. The company has developed proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell, to be implanted without the use of toxic immune suppressive drugs.
Provides integrated systems for nanotechnology-based cancer therapy.
The company utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties.
Develops nanoparticle based in vivo delivery applications.
MyLife Technologies are developing and commercializing a platform technology based on nanoporous MicroNeedle Arrays (npMNAs), integrated into a patch for drug delivery through the skin.
This start-up is focussed on tumor-specific nanoparticle platforms to largely improve delivery efficiency, treatment efficacy and product safety.
Dedicated to finding new treatments for cancer based on the combined application of nanotechnologies and biotechnologies.
Applies the manufacturing technology of ultrafine particles termed 'micellar nanoparticles' to use them as carriers for drugs, such as anticancer agents.
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization services. The company?s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nanonized 'designed-for-purpose' API particles, as small as 10nm.
NanoMedical Systems (NMS) is a startup company, which will commercialize the patented research of Dr. Mauro Ferrari at the University of Texas Health Science Center in Houston, a sponsored research site and a source of licensed IP for NMS. The company's Personalized Molecular Drug-delivery System (PMDS) is a small drug delivery device that is implanted subcutaneously (just under the skin) for slow and consistent release of a therapeutic agent over many weeks or months. A nanochannel delivery system (nDS) embodied on a silicon chip regulates the flow of therapeutic molecules.
Develops a therapeutic medical device which incorporates a new class of microparticles/nano-shells to selectively destroy solid tumors.
A nanobio-pharmaceutical company utilizing nanoscale materials and processes to develop anti-viral drugs against a wide range range of human and animal viruses.
OZ Biosciences creates, develops and produces innovative tools based on drug delivery systems for the worldwide scientific community and pharmaceutical industry. OZ Biosciences focuses on technologies for the delivery of bioactive materials into living organisms.
PDS Biotechnology Corporation is a biopharmaceutical company applying the company's platform Versamune nanotechnology to a new class of safe, simple, potent and targeted immunotherapies for the treatment of cancer and infectious diseases.
Develops a Protected Graft Copolymer (PGC™) nano-carrier drug delivery system.
The company is specialized in developing cutting-edge nanoparticle technologies for the development of targeted drug delivery systems.
Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.
Savara is is an inhalation drug development company developing next generation respiratory therapeutics utilizing its proprietary NanoCluster dry-powder formulation technology.
Thecompany performs research and development within nanomedicine. Focus is the development of nanomaterials for tumor diagnostics and treatment of cancer. The main development projects SpagoPix and Tumorad are both built on proprietary nanomaterials.
The company designs and develops drug delivery systems, among them self-nanoemulsifying systems.